Kinnate Biopharma (Kinnate Biopharma) Equity-to-Asset : 0.92 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kinnate Biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kinnate Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $159.33 Mil. Kinnate Biopharma's Total Assets for the quarter that ended in Dec. 2023 was $173.61 Mil.

The historical rank and industry rank for Kinnate Biopharma's Equity-to-Asset or its related term are showing as below:

KNTE' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23 Med: 0.89 Max: 0.98
Current: 0.92

During the past 6 years, the highest Equity to Asset Ratio of Kinnate Biopharma was 0.98. The lowest was -0.23. And the median was 0.89.

KNTE's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs KNTE: 0.92

Kinnate Biopharma Equity-to-Asset Historical Data

The historical data trend for Kinnate Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kinnate Biopharma Equity-to-Asset Chart

Kinnate Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.23

0.98

0.87

0.80

0.92

Kinnate Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial														0.80	0.91	0.91	0.90	0.92

Competitive Comparison of Kinnate Biopharma's Equity-to-Asset

For the Biotechnology subindustry, Kinnate Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kinnate Biopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kinnate Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Kinnate Biopharma's Equity-to-Asset falls into.

Kinnate Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Kinnate Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	159.327	/	173.605
	=

Kinnate Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	159.327	/	173.605
	=

Kinnate Biopharma (NAS:KNTE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Kinnate Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Kinnate Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kinnate Biopharma (Kinnate Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kinnate Biopharma Inc (NAS:KNTE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA, USA, 94129

Website

https://www.kinnate.com

Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.

Executives

James B. Tananbaum	director, 10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Orbimed Asia Gp Iv, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY 10022
Orbimed Advisors Iv Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Viii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Richard Thomas Williams	officer: Chief Medical Officer	C/O KINNATE BIOPHARMA INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Helen Sabzevari	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Neha Krishnamohan	officer: Chief Financial Officer	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164